Breast cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor, Gefitinib, suffered relapses, which were due to MAPK inhibition that paradoxically lead to PI3K/AKT activation [21]. This evidence concerns the gene AKT1 and breast carcinoma.